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ABSTRACT
Placenta-derived stem cells have been proposed as potential new treatments for 
acute and congenital liver diseases. Of all the different perinatal tissues, amnion 
membrane and isolated amnion epithelial cells have been shown to be an outstand-
ing readily available source of multipotent stem cells. Human amnion epithelial 
cells (hAEC) have unique properties, including low immunogenicity and immu-
nomodulatory properties, which may allow the first allogenic stem cell therapy 
without immunosuppression. Animal studies have shown that hAEC differentiate 
into hepatocyte-like cells and support missing liver functions commonly responsible 
for inborn errors of metabolism. In the present thesis, we describe early preclinical 
steps which will likely be necessary to translate hAEC therapy into clinical practice. 
These steps include detailed and optimized methods for primary hAEC isolation 
and preservation, methods to validate the final cell product and investigations 
of the route of infusion for efficient engraftment in the target organ (liver). The 
efficacy of hAEC transplants was assessed in preclinical models of liver disease. 
In Project 1, we have detailed the hAEC isolation procedure with GMP reagents, 
providing a homogenous amnion epithelial cell suspension. The preclinical vali-
dation of hAEC-based therapy was continued in Project 2, where 14 different 
batches of primary hAEC were characterized by immunocytological and biomo-
lecular techniques. The presented findings indicate this technology results in an 
enriched suspension of epithelial cells with a minimal contamination with mes-
enchymal, endothelial or hematopoietic cells. In Project 5, we validated the route 
of infusion of hAEC to reach high level of engraftment in liver. We investigated 
the bio-distribution of injected DiR-labelled hAEC administered via tail-vein or 
intra-splenic, and monitored their localization using in vivo live imaging (IVIS) 
techniques. Twenty-four hours post-splenic infusion, the majority of hAEC was 
safely delivered and detected in the liver parenchyma. On the contrary, tail-vein 
infusion resulted in a wide distribution pattern to multiple organs. 
In Project 3, we have investigated the in vivo engraftment, long-term survival and 
hepatic maturation of hAEC. We have injected hAEC into a metabolic liver disease 
model of Phenylketonuria (PKU). This immune-competent PAH-deficient mouse 
develops a pathological level of phenylalanine (PHE) in the blood, which is com-
monly observed in PKU patients. We assessed hAEC engrafted into murine liver 
parenchyma out to 100 days. Such long-term survival resulted in significant cor-
rection of blood PHE levels in blood and a statistical complete correction or PHE 
levels in the brain. The described xeno-transplantation was carried out without any 
immunosuppressant regimen, and no signs of rejection were noticed.
Problems generating clinically relevant results by extrapolation of data from 
mouse models was also addressed in Project 4, we successfully generated a liver- 
humanized mouse model that faithfully reproduces the metabolic liver disease 
observed in patients. We injected hepatocytes isolated from a CPS1 deficient 
patient into immune-compromised mice (FRGN), where primary human hepato-
cytes have been previously reported to engraft and fully repopulate the mouse 
liver. The resultant chimeric CPS1-Deficient (CPS1-D) model exhibited high 
blood ammonia levels, elevated disease-correlated amino acids (glutamine and 
glutamate) and low CPS1 enzymatic activity. 
In conclusion, during the past 4-year study we have successfully analyzed pre-
clinical data and validated the hypothesis that human amnion epithelial cells are 
useful for the cellular therapy of liver disease, supporting their potential to become 
a therapeutic tool to treat and support metabolic liver disease patients. 
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11 INTRODUCTION
1.1 Liver
The liver is a vital organ. One cannot survive without a liver for more than a few 
hours. The liver is vital, because it performs many functions critical to sustain life 
including the regulation of blood glucose, ammonia metabolism and urea produc-
tion, the synthesis and secretion of plasma proteins including albumin and clotting 
factors and the metabolism and excretion of many endogenous substrates such as 
hormones, as well as xenobiotics (1) (Figure 1). Regenerative medicine is a term 
widely used to describe the biomedical approach to heal damaged tissue by either 
replacement of damaged cells, as with cell transplant techniques, or stimulating the 
repair activity of endogenous cells. Because of its extensive capacity to regener-
ate, the liver perhaps, more than any other organs offers a great opportunities in 
regenerative medicine. The primary cell type that performs the majority of liver 
functions is the parenchymal hepatocyte, which comprises approximately 60% of 
the cell number, and account for about 80% of the liver mass (1). The remaining, 
non-parenchymal cells include cholangiocytes (bile duct cells), Kupffer, stellate 
and endothelial cells. The liver also produces around 700ml of bile (2). This bile 
is collected in the bile duct and carried to the duodenum of the small intestine 
directly or via the gall bladder. Bile helps to breakdown and absorb fat in our diet. 
Figure 1. Pictorial representation of liver functions. Created with Biorender.com
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2.1 Liver Cirrhosis
Liver cirrhosis is characterized by deformity of the liver architecture, necrosis of 
hepatocytes and regenerative nodule formation. Cirrhosis is a late stage of  scarring 
of liver that is common to many liver diseases (3). Major reasons include exces-
sive alcohol consumption, viral hepatitis B or C, although there are other causes. 
Cirrhosis involves loss of liver cells and results in irreversible scarring of the liver. 
Orthotopic liver transplantation (OLT) is the ultimate solution for end stage liver 
disease. However, hepatocyte transplantation (HTx) pioneered by our laboratory 
is used as a bridge therapy for patients, who are awaiting for organ transplant. 
The liver architect is altered in liver cirrhotic patients, which makes HTx more 
complicated. 
2.2 Acute liver failure (ALF)
Acute liver failure (ALF) remains a condition with considerable mortality (4) 
and is a catastrophic illness that may lead to severe hepatic injury or massive 
necrosis, hepatic encephalopathy, and frequently, death (5). The term fulminant 
hepatic failure applies to patients who develops hepatic encephalopathy within 2 
months of the onset of liver disease such as jaundice (6). The chances of survival 
is mere 20%, where the only cure is OLT. Both viral hepatitis and drug induced 
liver injury are common reasons for ALF. 
2.3 Metabolic liver disease
Since many liver functions are necessary to sustain life, mutations in the genes 
that encode these liver proteins / enzymes can be life-threatening. Metabolic liver 
diseases can result when these critical liver functions are deficient or completely 
absent. Most metabolic liver diseases are the result of a single protein or enzymatic 
defect, with the remaining hepatic activities being carried out at normal levels (7). 
For example, a patient with phenylketonuria (PKU) has a mutation in the PAH gene 
which prevents the conversion of phenylalanine into tyrosine. All the remaining 
functions such as clotting factors or drug metabolism are performed at normal 
levels. Historically, severe metabolic liver diseases have been treated by HTx (8, 
9). The replacement of an entire liver to correct a single metabolic defect might 
seem excessive if there were other options to correct the defect which were equally 
effective but yet, less invasive. Here is where the concept of cellular therapy of 
liver disease began to be considered.
33 ORTHOTOPIC LIVER TRANSPLANTATION (OLT)
OLT has been the primary treatment for several end stage liver diseases and life 
threatening metabolic liver diseases for several decades. Despite the unquestioned 
success of OLT, the technique requires major surgery and takes a considerable recov-
ery period (10).
The shortage of organ donors and other surgical complications, immune rejection and 
infections post-transplantation are all limitations for OLT (11). Cell therapy has been 
proposed as an alternative treatment for liver diseases (12, 13). Cell transplantation 
is far simpler than OLT, it is less expensive, less invasive and the patient keeps their 
native liver. Thus, in a situation where the cell graft is lost through senescence or 
rejection, the patient is simply returned to the pre-transplant state (Figure 2). Perhaps 
the prime benefit of cellular therapy is that since the patient keeps their native liver, 
the donor cells need only support the one liver function missing in the recipient, and 
are not required to support the entire range of liver functions. Some of the benefits 
of cellular therapy are listed in Figure 2.
Figure 2. Advantages of cellular therapy of liver disease. Created with Biorender.com
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4.1 Hepatocyte transplantation (HTx)
The liver parenchymal cells are the preferred choice of cells for the cell therapy of 
liver disease. More than 20 years of preclinical studies with small animal  models 
have shown the safety and efficacy of hepatocyte transplants in the treatment of 
a variety of liver diseases. The first HTx in patients were carried out during the 
early 1990s (9, 12). Transplanted hepatocytes support the regeneration of the native 
liver and can also provide proteins or enzymatic activities missing in the recipient. 
The waiting time for patients to receive a suitable organ may vary from months to 
years and the numbers of patients that could benefit from organ replacement far 
exceed the availability of the donor organs. Thus, additional therapies are needed. 
HTx can bridge the patient and provide temporary liver support while waiting for 
a solid organ transplant. However, even with HTx, there are not enough useful 
livers available for cell isolation. This limitation with hepatocytes has led to a 
search for alternative sources of cells for this therapy.
4.2 Other cell sources
Multiple cell sources were proposed as an alternative source of cells for hepato-
cyte transplants. Among them, fetal hepatocytes, domino transplants, embryonic 
stem cells (ESC), induced pluripotent stem (iPS) cells, and human amnion epithe-
lial cells (hAEC). Since even a few remaining undifferentiated pluripotent stem 
cells are capable of forming a tumor upon transplantation, the use of ESC or iPS 
cells remain at the preclinical stage with respect to liver disease. Also, there are 
no protocols published that describe the generation of hepatocyte-like cells from 
these stem cells with fully mature liver functions (14). Fetal hepatocytes do not 
express mature liver functions and are associated with some ethical concerns for 
their collection and use. Domino hepatocyte transplants have been conducted on 
two patients with PKU with cells isolated from patients with different metabolic 
liver diseases, but this source of cells, while useful, will not provide the numbers 
of cells needed for cellular therapy of liver disease (13, 15). 
55 PLACENTA
The close relationship between the fetus and the mother is an important phenom-
enon in human development. The fetus has to establish an intimate relationship with 
the mother in order to get enough nutrients, oxygen and to discard waste products. 
The placenta is the medium that helps the fetus and importantly, protects the fetus 
from the mother’s immune system; otherwise, it would be rejected since the fetus 
is a semi-allograft (16).
 
Figure 3. The numbers of caesarian-section procedures occurring in different countries 
per 1000 births. Data were obtained from the Organization for Economic Co-operation 
and Development (OECD) countries and are according to 2016 statistics.
The placenta is a tissue that provides nutrients and oxygen exchange between the 
fetus and mother through the umbilical cord (16). The proper function of the placenta 
is crucial for a successful, full-term pregnancy. The placenta is dark reddish in color 
with 20-22 cm in length, 2-2.5 cm in thickness and usually weighs around 500-600g. 
The placenta is composed of three layers: amnion, chorion, and decidua respectively 
(Figure 4). 
Amnion and chorion are membranes of fetal origin whereas decidua is a maternal 
tissue adherent to the chorion membrane. Amnion membrane continues from the 
edge of the placenta and encloses the amniotic fluid and the fetus (16). Several 
types of stem cells can be isolated from full-term placentae such as human amnion 
epithelial cells, human amnion mesenchymal stromal cells, chorionic mesenchymal 
stromal cells, and hematopoietic stem cells (17). 
6Advantages of using placental derived stem cells is the lack of ethical concerns. 
Unlike embryonic stem cells, the ethical problems can be overcome with these 
placenta derived cells since the placenta is usually discarded after delivery.
5.1 Amnion membrane
By approximately day 8 after fertilization, the inner cell mass begins to segregate 
into epiblast and hypoblast layers. Concomitant with this, the amnion epithelial 
cells differentiate from the epiblast (Figure 5) (18). The amnion cavity develops 
within the epiblast and the cells adjacent to the amniotic cavity, termed amnioblasts, 
proliferate and finally become a thin, tough, elastic, avascular amniotic membrane 
(AM ) (19). AM has several favorable properties for clinical applications such 
as anti-fibrotic, anti-inflammatory and pro-regenerative effect (20). The AM can 
be used before and after cryopreservation without any difference in their clinical 
potential features (20). AM has been used for patching liver to counteract liver 
fibrosis (20), wound healing such as fire burns (21), also used to promote corneal 
healing in severely damaged eye (22).
Figure 4. Human placenta. The amnion membrane getting separated from the chorion 
layer. The amnion membrane stained with H&E (top panel) and histology section of three 
layers of placenta (bottom panel). (R. Gramignoli, Curr Pathobiol Rep 2016. 4:157-167)
 
Figure 4: Human placenta. The 
amnion membrane getting separated 
from the chorion layer. The amnion 
membrane stained with H&E (top 
panel) and histology section of three 
layers of placenta (bottom panel). 
(Gramignoli et al., 2016) 
7The AM is an uninterrupted single layer of columnar epithelial cells in contact with 
amniotic fluid. The AM can be subdivided into five anatomic layers: the epithelial 
cell monolayer, an acellular basement membrane layer, a compact layer (basal 
lamina), dispersed stromal cells (mesenchymal cell layer) and a spongy layer which 
is located close to chorionic membrane. 
Both the amnion epithelial and mesenchymal cells possess stem cell characteristics 
and immunomodulatory properties which has attracted the attention for regenerative 
medicine applications (18).
Figure 5. Embryogenesis from fertilization to gastrulation. Created with Biorender.com
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6.1 Origin
The hAEC have several features that make them attractive for cell therapy. The 
availability of hAEC is plentiful, and their collection and use are non-controversial 
(18, 23). In the field of regenerative medicine, there are many potential sources of 
cells available for clinical studies and application, such as ESC or iPS. Although 
their biological potential have been demonstrated, still these cells are not widely 
accepted for clinical treatments. 
The origin of hAEC makes them unique and these cells possess plasticity that 
allows them to differentiate into all three germ layers (18). In special conditions, 
in vitro, the hAEC can differentiate into ectoderm (neural cells) (24); mesoderm 
(cardiomyocyte) (18, 23); endoderm (liver and pancreas) (23). There are numerous 
reports of hAEC adopting hepatic characteristics, in vitro, or upon transplantation, 
in vivo. Ours, and several other groups have reported the expression of genes that 
are normally expressed in the mature liver (25, 26). Properties listed in Figure 6 
support the use of hAEC for regenerative medicine.
Figure 6. The advantages of using human amnion epithelial cells in regenerative 
 medicine. Created with Biorender.com 
6.2 Stem Cell Properties
The origin of amnioblast from the epiblast happens prior to gastrulation, the point 
where the three germ layers are specified (27). This unique development of hAEC 
prior to tissue specification may explain their multipotent nature. 
9The hAEC express surface markers that are also normally expressed in embryonic 
stem cells including tumor rejection antigens (TRA) 1-60 and 1-81. The hAEC 
also express stage-specific embryonic antigens (SSEA)-3 and -4 (18). Apart from 
these surface markers, hAEC were also reported to express genes commonly 
expressed in pluripotent stem cells, including Octamer binding protein 4 (OCT-4), 
sex-determining region BOX 2 (SOX-2) and NANOG; genes are known to be 
important for maintaining pluripotency (18). 
6.3 Tumorigenicity
Tumorigenicity is one of the major hindrances in using pluripotent stem cells in 
cell-based regenerative medicine therapies, since they may cause formation of 
tumors due to their immortal nature. On the other hand, hAEC do not express 
telomerase reverse transcriptase (TERT), they are not immortal and do not form 
tumors upon transplantation (unlike ESC and iPS). Tumorigenicity of hAEC was 
evaluated by injecting 1 million hAEC in large numbers of SCID mice that were 
kept under observation for 7 months (18).
6.4 Immune Privilege
Immune rejection is a major limitation for liver transplantation. Under normal con-
ditions, the host’s immune system will identify the transplanted cells as foreign and 
will initiate an immune response to eliminate them. The Immune privilege status 
of hAEC may break barriers in cell therapy and may save patients from lifelong 
immunosuppressive drugs (28). Human Leukocyte antigens (HLA) plays a major 
role in the immune system. They are divided into two types, HLA I and HLA II 
respectively. The HLA molecules are referred to as ‘transplantation antigens’, and 
their presence on the transplanted cells may lead to immune-mediated rejection (29). 
6.4.1 Low Immunogenicity
When transplanted, hAEC have displayed low immunogenicity. Nature has evolved 
a mechanism to protect the fetus from the mothers’ immune system (Figure 7). 
Generally, rejection of cells or organs occurs due to mismatch of HLA expression 
from the host immune system. Unique characteristics of hAEC are that they express 
low levels of HLA class Ia molecules; HLA A, B, C, and express significant levels 
of less common HLA class Ib molecules -E, -F, -G which are potent immunomodu-
lators. They do not express human leukocyte antigen class II (HLA-DP, DQ and 
-DR) antigens and the co-stimulatory molecules, CD40 and CD80 (16, 30).
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To examine their immunogenicity and survival, hAEC were transplanted into seven 
volunteers, six men and one woman, by Akle et al 1981. There was no sign of 
acute rejection and the survival of hAEC was demonstrated out to 7 weeks post-
transplantation by biopsy (31). 
6.4.2 Human Leukocyte Antigen-G
The fetus is semi-allograft since it contains the genetic material from the father 
and the mother. In normal conditions, even semi-allografts would be considered as 
foreign and rejected by the host immune system. However, under normal conditions 
the fetus can grow within the mother for the entire duration of pregnancy without 
immune-related problems or rejection. One of the major reasons for this tolerance 
is thought to be HLA-G, a key factor for fetal-maternal tolerance. HLA-G is a 
non-classical, non-polymorphic HLA class 1b antigen that is critical in regulating 
the tolerance of the fetus by the maternal immune system (32).
 HLA-G has been identified as a ligand for two inhibitory receptors namely, ILT2 
and ILT4 (CD85j and CD85d) and the receptor KIR2DL4/CD158d (33-35). The 
receptor KIR2DL4/CD158d is a HLA-G specific receptor and ILT2 and 4 have the 
highest affinity for HLA-G (36). It is commonly believed that these three recep-
tors for HLA-G play an inhibitory role on the immune system. Natural killer (NK) 
cells express the KIR2DL4 receptor and it can act as an activating receptor on NK 
cells and results in upregulation of IFN-γ production (36). Also, interferon-gamma 
(IFN-γ) can provoke the the immunosuppressive effect of hAEC by inducing 
indoleamine 2, 3-dioxygenase (IDO) activity. 
Because of these direct and indirect effects in immune regulation, HLA-G has been 
proposed as a therapy for solid organ and cell transplantation. HLA-G is present 
in and on hAEC both in a soluble, as well as membrane-bound form. 
6.4.3 Immunomodulatory Effect
In addition, hAEC also directly or indirectly modulates the inflammatory signals 
that result in tissue rejection. Amnion epithelial cells derived factors have the ability 
to inhibit neutrophils and macrophages in vitro (37). Macrophage-inhibitory factor 
(MIF), which is a potent inhibitor of macrophage migration is released by hAEC. 
It was also shown that MIF is a potent inhibitor for natural-killer cells mediated 
lytic activity (38). When T and B cells were incubated with hAEC supernatant, 
there is 6-7 fold increase in T and B cell apoptosis when compared with untreated 
controls (37). Dendritic cells (DC) plays an important role in presenting antigens 
to T cells. Monocytes exposed to DC maturation in the presence of amniotic 
membrane-derived cells results in impaired development of DC (39).
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Figure 7. Immunomodulatory/Immunosuppressive properties of hAEC. The hAEC 
express several factors to suppress T and B cells proliferation such as TGF- ß, FasL, 
TRAIL, MIF. It also expresses HLA-G, which suppresses the proliferation of CD4+ cells 
and induce apoptosis in CD8+ cells. Also, FasL binds to the FasR on activated the host 
immune cells which results in cell apoptosis. The hAEC are known to modulate the host 
immune system by increasing IL-10, IL-6 and other cytokines. Created with Biorender.com
The hAEC secrete other immunosuppressive factors such as prostaglandin E2 
(PGE2), which has several immunosuppressive properties such as inhibition of T 
cell proliferation. PGE2 stimulates the production of Th2 cytokines which signifi-
cantly elevates Interleukin 5. The hAEC secrete transforming growth factor-beta 
(TGF-ß), a T cell growth inhibitor and a powerful immunosuppressive molecule 
(40). The hAEC also secrete other immunosuppressive factors including several 
interleukins (40, 41). Other immunoinhibitory molecules were reported to be 
expressed by hAEC, including CD59 and Fas ligand (FasL) (42, 43). Fas ligand 
is a peptide that plays an important role in immune modulation and limits the host 
immune response by binding to the Fas receptor on activated host immune cells 
leading to apoptosis (43). The hAEC express CD59 on their surface that prevents 
the lysis of the hAEC by inhibiting the host complement system. CD59 prevents 
the formation of the C9 polymerization complex, which is required for formation 
of the complement membrane attack complex (42).
12
6.5 Hepatic Differentiation of hAEC
The hAEC has several characteristics that makes them stand out among the other 
sources of stem cells available in the field of regenerative medicine. They are 
multipotent, have immunosuppressive properties, and are non-tumorigenic. 
It has also been reported that hAEC can differentiate into hepatocyte-like cells 
under certain conditions (18, 25, 44). hAEC express significant levels of SOX-2, 
OCT-4, and NANOG and these genes diminish at the end of hepatic differen-
tiation procedures and the cells begin to express mature hepatic genes. Another 
study showed that these cells can differentiate in vivo to cells with characteristics 
of mature hepatocytes. Importantly, amnion epithelial cells do not fuse with the 
host parenchymal hepatocytes when transplanted as determined by histological 
analysis (26). The cells were further analyzed by RT-qPCR to confirm the expres-
sion of albumin, cytochrome P450 and other liver genes (26). 
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7 CRYOPRESERVATION 
Cryopreservation of cells is necessary to preserve structurally intact cells at very 
low temperatures for a long period of time (9, 45). Cryopreserved cells, available 
for immediate use, would be important for patients with ALF when an organ or 
hepatocytes are not available, and for repeated scheduled transplants for metabolic 
liver disorders. An added advantage of using cryopreserved cells is that each cell 
batch can be individually analyzed and characterized according to the release criteria 
established for the transplantation of the cells. Thus, a cell bank can be established 
containing only those cells that meet all the criteria for use in a clinical transplant. 
These characterization steps can be accomplished long before the cells are actually 
needed for a transplant procedure. 
However, the cryopreservation procedure can result in the formation of intracellular 
ice crystal, which leads to dehydration of cells. This can lead to cell rupture, necrosis, 
and apoptosis. The optimization of the cryopreservation solution, the cryoprotectant 
and freezing rate can minimize the damage to the cells. 
7.1 UW Solution
University of Wisconsin (UW) solution was developed during the late 1980s by 
Belzer and colleagues at University of Wisconsin for the cold storage and transport 
of organs prior to transplantation. Later, UW solution was adopted for the cryopreser-
vation of hepatocytes (9,12) and later, (46). Besides its effectiveness, an advantage 
of this solution for a clinical study is that the solution is produced and sold as a 
pharmaceutical-grade solution, which is approved for use on cells, which will later 
be transplanted into patients. The efficacy of the cryopreservation procedure depends 
not only on the cryopreservation solution but also on the nature of the cells being 
cryopreserved. Simple cells with few organelles such as fibroblasts or tumor cells 
generally cryopreserve easily, while complex cells such as hepatocytes, with many 
different organelles, all which might freeze at different rates, are generally more 
sensitive to cryopreservation procedures. Successful cryopreservation also depends 
on the cryoprotectants used, the freezing rate and thawing procedures. There are 
other commercially available cryosolutions, including cryostore, stem cell banker 
are also used for cryopreservation (47, 48). The Institut Georges Lopez (IGL) solu-
tion is also commercially available cryosolution, which is similar to UW solution 
although it is lower in potassium and viscosity (49).
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7.2 Cryoprotectant
Cryoprotectants are generally used to protect the cells from freezing damage. 
Naturally, amphibians and fish in Arctic and Antarctic regions produce anti-freeze 
compounds in their body (mainly sugars) to reduce the damage caused by freez-
ing. Mammalian cells are not suited for direct cryopreservation. When the cells 
are cryopreserved, they tend to form intracellular ice crystals. The ice formation 
is avoided and flexibility is maintained by the cryoprotectant reagents (50, 51). 
Dimethyl sulfoxide (DMSO) is as a commonly used and accepted cryoprotectant 
reagent. The final concentration of 10% DMSO is generally used in protocols (50, 
51). In addition to DMSO, there are various cryoprotectants being used for long-
term storage for liver cells. Glycerol, fetal bovine serum, sucrose is also used as a 
cryoprotectant along with cryopreservation solutions without DMSO (52). 
7.3 Freezing Rate
The cells are cryopreserved in a controlled rate freezer instead of rapid freezing. The 
temperature is lowered to -80°C at a controlled rate of -1°C per min. Subsequently, 
cells are moved to -150°C (vapor phase of liquid nitrogen storage tank). 
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8 AMNION EPITHELIAL CELLS IN PRECLINICAL 
STUDIES
Preclinical studies have to be conducted to take hAEC further as a real tool for cell 
therapy. Preliminary studies on animal models with active immune system help us 
to expand the knowledge on hAEC and to understand the characteristics of the cells 
in vivo, handling of the cells for transplantation and potential of the cells.
The hAEC have gained recognition as an alternative to whole organ transplanta-
tion in acute liver failure, chronic liver disease and metabolic disorders (28, 53). 
Preclinical studies have been conducted with mouse models and showed hAEC 
are effective and likely safe for clinical transplant. Animal models that mimic 
conditions in human metabolic liver diseases including Maple syrup urine disease 
(MSUD), Phenylketonuria (PKU) and acute liver failure were corrected by hAEC 
transplants (28, 54).
8.1 Site of Administration
One of the important strategies in cell therapy of liver disease is to deliver the cells to 
the liver with minimal leakage to other organs. The most common site for transplant-
ing cells are the spleen and liver. However, the transplantation site is chosen based 
on the liver architecture. The route of administration must be carefully considered 
when developing cell therapies. For hepatocyte transplants, an intraportal route is 
preferred for clinical transplants (55). This can be accessed by puncturing the portal 
vein with a catheter. In younger patients the liver can also be accessed through the 
umbilical vein (56). When the liver architecture is altered as in the patients with 
 cirrhosis, hepatocyte transplantation may lead to embolization of the portal veins and 
portal hypertension. There are alternative sites that can be used for cirrhotic patients 
such as the splenic pulp or splenic artery, or the  peritoneal  cavity (9, 12, 57, 58). In 
animal models, the intraportal route is preferred via spleen to achieve better bio-
distribution of the cells in the liver. When there is a need for multiple transplants 
of cells, cells can be directly transplanted to the liver. 
8.2 Bio-Distribution
To improve the efficiency of cell therapy and to minimize side effects, it is impor-
tant to optimize the route of administration of cells and confirm the transplanted 
cells reach the target organ, in this case, the liver. There is a need for reliable, non-
invasive methods to evaluate the bio-distribution, migration, and engraftment of the 
cells after transplantation. Non-invasive imaging techniques are designed for track-
ing the transplanted cells and to determine their bio-distribution. Bio-distribution 
studies were performed with different cell types including embryonic stem cells, 
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hepatocytes and mesenchymal stromal cells with different reporter markers such 
as near infra-red dye (NiR), 111-Indium labeling and magnetic resonance imaging 
(MRI) (59-64). For better understanding of hAEC, a bio-distribution study was 
published by our group recently (65). The majority of hAEC transplanted reached 
the liver when they were infused into the portal vein via the spleen. Migration 
of cells is negligible to other organs. To move forward with preclinical studies, 
mouse models with metabolic liver diseases were used to investigate the efficacy 
of hAEC transplants to correct the symptoms of the genetic disease. 
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9 ANIMAL MODELS TREATED WITH HAEC
9.1 Phenylketonuria (PKU)
The deficiency of phenylalanine hydroxylase (PAH) occurs due to mutation in the 
PAH gene. It is an autosomal recessive disorder, i.e. parents are frequently the car-
riers of the disease, although they usually do not suffer from the mutation. With de 
novo mutations, or when both the parents transmit the mutant gene, it can result in 
PKU in the child. The level of the deficiency depend on the nature of the mutation, 
which may result in serious PKU or mild hyperphenylalaninemia. The prevalence 
of PKU is 1 in 10,000 in Europe and a higher incidence found in turkey with 1 
in 4,000 births and less common in African and Asian populations (https://www.
orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=716). 
The mutation results in the inability to metabolize phenylalanine to tyrosine. The 
lack of PAH expression, or the production of mutant protein results in high pheny-
lalanine levels in the blood and brain that cause neurological problems (66). In 
contrast, tyrosine is not produced significantly and it is required for proper neural 
development since it is an important enzyme for synthesis of neural transmitters 
(Figure 8).
Figure 8. Pictorial representation of phenylalanine built up due to the PAH deficiency 
and in- contrast, insufficient tyrosine synthesis. Created with Biorender.com
There is a mouse model for PKU that carries the same mutation as many human 
PKU patients, and the affected mice show many of the same symptoms of the 
disease as the PKU patients. In our studies, the pups were transplanted with previ-
ously cryopreserved hAEC directly into the liver. There was no immunosuppres sion 
provided when transplanting hAEC even though the mouse has a normal immune 
18
system. This is one of the major advantages of hAEC cell therapy since with other 
cells, rejection is a major hindrance. When PKU mice were transplanted with 
hAEC there was a significant correction of the phenylalanine levels in the blood 
and brain. The mice were kept under observation for one hundred days without any 
sign of rejection or inflammation. The transplants of hAEC reduced brain pheny-
lalanine to levels that are not significantly different from un-affected, wild-type 
animals (28). Organs were harvested for further analysis of hAEC. Gene expres-
sion profiling showed that hAEC expressed all 63 genes examined at levels that 
are expressed in mature liver cells.
9.2 Maple Syrup Urine Disease (MSUD)
Another severe metabolic liver disease, MSUD, is an autosomal recessive disorder 
of amino acid metabolism. It is estimated around 1 in 185,000 infants worldwide 
are affected with this metabolic disorder. This metabolic disorder gets its name 
because of the affected infants’ urine smell with a distinct sweet odor. The dis-
ease is caused by the inability to metabolize branched-chain amino acids and is 
characterized by the accumulation of branched-chain amino acids (BCAA) in the 
blood and brain. Untreated individuals can experience neurological abnormalities, 
seizures, and ultimately, death (67). Currently, the disease is treated primarily with 
lifelong diet control with BCAA restriction. 
MSUD results due to deficiency in the branched-chain-αketo acid dehydrogenase 
(BCKDH) complex. This mutation results in inability to process branched-chain-
αketo acid (BCKA). This BCKA is derived from BCAA; leucine, isoleucine, 
and valine, respectively. The accumulation of BCAA is depended on the level of 
BCKDH deficiency which results in sweet maple syrup odor in the urine (53). 
Animal models are useful to understand and explore the mechanism of disease 
and for preclinical studies. A mouse model was developed with a partial knockout 
of BCKDH. Our group previously reported the correction of MSUD by hepato-
cyte transplantation and extended these studies to include hAEC transplantation 
as a substitute for hepatocytes in these procedures. As with the transplantation 
of authentic hepatocytes, hAEC transplants resulted in increased survival of the 
animals as well as the correction of the BCAA in serum and brain (54, 68). 
9.3 Acute Liver Failure
Acute liver failure is severe and rapidly progressing liver failure that is frequently 
treated by liver transplantation. The primary problem in ALF is the absence of 
parenchymal hepatocytes and this cell mass is need to support the metabolic 
requirements until the liver regenerates or a donor liver is available for transplant. 
Here, hAEC can provide an exogenous source of cells that can provide immune 
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modulation and ultimately, hepatic function to support the host liver and correct 
liver failure. Once the native liver starts to regenerate, OLT might not be needed 
and hAEC therapy can be done without immunosuppression. 
Our group has reported earlier, hAEC can rescue the mouse model of ALF. A 
reproducible mouse model of ALF was generated by injecting a dose of d-galac-
tosamine (d - gal) and that is 100% fatal to the mice if they were untreated. Mice 
were infused with 2 million hAEC via spleen 6h after the d-gal treatment (28). 
All mice that received only d-gal died within 72h, while 100% of the mice that 
received hAEC transplants survived the d-gal treatment (28). These preclinical 
studies cited above demonstrate the efficacy of hAEC in the treatment of acute 
and chronic, metabolic liver disease. 
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10 AMNION EPITHELIAL CELL THERAPY OF 
OTHER TISSUES
Apart from liver, hAEC is also used for several diseases affecting different organs. 
In a mouse model, lung injury was induced with bleomycin and hAEC transplants 
reduced the inflammation and severity of disease (69). Recently, a human trial with 
hAEC was successfully performed in six premature babies with Bronchopulmonary 
Dysplasia (BPD) (70). Lung fibrosis was successfully prevented and the hAEC 
were well tolerated and there was no evidence of tumor formation and no adverse 
effects were observed in any of the babies. In other studies, hAEC were shown to 
differentiate to neuronal-like cells, synthesize and release catecholamine; a neural 
transmitter that serves in transferring signals between neurons (71). This makes hAEC 
a potential candidate for neural related disease such as Parkinson disease (71) (72).
Diabetes mellitus has become a serious threat to human health. Replacing the lost 
Beta cells with functional insulin-producing Beta cells is a novel therapy that could 
provide a cure for patients with Diabetes mellitus. It has been reported, that when 
a patient with type I Diabetes mellitus was treated with amniotic cells, the patient 
remained independent of insulin intake for 6.2 months and later, insulin require-
ments were readjusted to 8 IU/day post-transplantation compared to 38 IU/day, 
pre-transplant (73). It was also reported, that hAEC have the potential for wound 
healing (74), and the correction of heart disease (75), stroke (76) multiple sclerosis 
(40) and many other diseases (Figure 9).
Figure 9. Pictorial representation of 
amnion tissue and cells used to treat 
the medical problem. S.C. Strom and 
R.Gramignoli, Human Immunology 
77 (2016) 734-739 
Figure 9: Pictorial representation of 
amnion tissue and cells used to treat the 
medical problem. SC.Strom and 
R.Gramignoli, human immunology 77 
(2016) 734-739 
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11 ANIMAL MODELS 
Animal models are used to study the development and progression of disease and 
are used to test new medications and treatments before they are given to humans. 
There are multiple factors that affect liver function and billions of dollars are spent 
across the world in medical care to treat liver-related diseases. There are large dif-
ferences in metabolic pathways involved in xenobiotic metabolism and excretion 
between the commonly used animal models and humans. Experiments with mouse 
models may not faithfully predict what occurs in humans. Recent developments in 
animal models have resulted in creating mouse models with genetic alterations that 
result in damage and loss of native hepatocytes. Under appropriate conditions, the 
loss of the mouse hepatocytes creates a strong liver regeneration response that sup-
ports the complete replacement of the mouse hepatocytes with human hepatocytes 
in the liver of these mice.
11.1 Humanized Mice
To address these issues, several groups tried to make chimeric mice with ‘Humanized 
liver’ by engrafting and expanding primary human hepatocytes in rodents. Markus 
Grompe, Strom and co-workers developed a model with a Fah knockout mouse that 
was crossed with Rag2-/- (recombinant activation gene 1) and Il2rg-/- (interleukin 
receptor 2 subunit gamma) mice that result in triple mutants Fah/Rag2/Il2rg (FRG) 
mice. The mouse is profoundly immunodeficient and will accept the transplantation 
of cells from different species, including human (77). Also, the murine Fah muta-
tion is equivalent to the severe metabolic liver disease, Hereditary Tryosinemia type 
1( HT1). Like human HT1 patients, the mice will not develop liver disease while 
they are maintained on the protective drug 2-(2-nitro-4-trifluoromethylbenzoyl)-1, 
3-cyclohexanedione (NTBC). However, when NTBC is withdrawn, the mice go 
into liver failure and can be rescued by the transplantation of FAH-proficient human 
hepatocytes (77). In this model, the mouse hepatocytes can be nearly entirely 
replaced as the mouse liver becomes repopulated with human hepatocytes. Later 
studies incorporated the non-obese diabetic (NOD) mouse background into the 
FRG strain to generate the FRGN mouse. The additional presence of the NOD 
background enables a greater acceptance of human cells as compared to the normal 
FRG strain (78). The liver-humanized mice are useful models for drug metabolism 
and excretion and toxicity studies (79, 80). The FRGN model is also useful for 
the bio-distribution studies since immunosuppressive drugs are not required even 
when the animals receive xenotransplats of human cells, such as hAEC.
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12 AIM AND SIGNIFICANCE
The overall aim of this thesis is perform basic, preclinical studies of the safety 
and efficacy of hAEC transplants to treat liver diseases and to set a basis for more 
targeted studies to translate human amnion epithelial cells to the clinic. Amnion-
derived cells have been characterized and validated as a homogenous population 
after isolation procedure, while in vivo studies demonstrated their ability to dif-
ferentiate into functional hepatocyte-like cells. The hAEC could have a substantial 
impact on the cell therapy field.
The objective of individual papers are as follows:
PAPER 1: 
• To standardize and optimize a cell isolation protocol for manufacturing 
hAEC under GMP-like conditions.
PAPER 2:
• To validate the cryogenic procedures for primary human amnion epithelial 
cells. 
PAPER 3:
• To evaluate a hAEC-based treatment of the congenital liver disorder (PKU) 
in a relevant mouse model. 
PAPER 4:
• To generate a liver-humanized mouse model for carbamoyl phosphate syn-
thetase I deficiency and determine if it faithfully recreates the human disease.
PAPER 5:
• To validate efficient and safe routes for infusion of hAEC into the liver.
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13 METHODOLOGY
13.1 Primary cells
13.1.1 Murine And Human Hepatocyte Isolation
The mouse hepatocyte isolation was performed by in situ perfusion of the liver 
by a three-step collagenase perfusion protocol. Briefly, the first solution consist 
of Hank’s Balanced Salt Solution (HBSS) supplemented with 1 mM ethylene 
glycol tetraacetic acid (EGTA), a calcium chelator which helps in disrupting the 
intracellular connections by removing the calcium. A second solution of HBSS 
is supplemented with calcium since it is required for collagenase to function and 
to remove the EGTA from the liver. Finally, a third solution of HBSS containing 
collagenase type 2 (1 mg/mL), is used to disrupt the extracellular matrix. 
A retrograde perfusion of the liver is accomplished by inserting a catheter into the 
inferior vena cava with additional occlusion of the upper vena cava with a clip. 
A transection of the portal vein allows perfusate to escape the liver. Perfusion 
solutions were kept at 37°C in a water bath. Digestion of the liver takes about 8 
to 12 min depending on the mice. The digested liver was transported to the lab in 
cold HBSS on wet ice and chopped with a scissors in a sterile beaker to release 
cells. The cells were centrifuged at 90 g for 5 min with two additional washes and 
centrifuged at 4 °C. The cells were counted and cryopreserved using UW solution 
supplemented with 10% DMSO. 
All human tissues were collected with informed consent following institutional and 
ethical guidelines (ethical protocol 2014/1561-32). Organ donors and explanted 
tissues were tested for hepatitis viruses B and C, and human immunodeficiency 
virus (HIV) and resulted negative. All human hepatocytes were isolated as previ-
ously described (81), and immediately after isolation were seeded in culture plates 
or cryogenically preserved using University of Wisconsin solution (BEL GEN 
1000, Lissieu, France) supplemented with 10% DMSO (Sigma-Aldrich, St. Louis, 
MO, USA). Hepatocytes were thawed on the day of transplantation in a 37 °C 
water bath until the ice is barely visible and cells are diluted with 10 volumes of 
cold Williams medium E supplemented with 10% calf serum and centrifuged at 
90 g for 5 min at 4 °C. The cell pellet was suspended in cold plasmalyte (Baxter, 
Norfolk, UK) for transplantation.
13.1.2 Murine Transplantation Procedures
For intra-splenic transplants, mice were anesthetized using isoflurane (Baxter, 
Norfolk, UK) and a small incision was made on the left abdominal region and 
the tip of the spleen was exposed. The cells were infused slowly into the splenic 
parenchyma. Cell leakage or overflow of cells was prevented by placing the 
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cotton-tipped applicator on the injected site for a few seconds. The spleen was 
placed back in the abdominal cavity and the incision was closed with absorbable 
sutures (Ethicon, Diegen, Belgium). For tail vein infusions, mice were placed in 
a restrainer and cells were infused by a syringe with a 29 gauge needle. All trans-
plant events required an infusion procedure not longer than 40 sec. Transplants 
consisted of one million (viable) cells re-suspended in 200µl plasmalyte solution 
with 15 units/mL heparin (Orifarm AB, Stockholm Sweden) 
13.1.3 Human Amnion Epithelial Cells
Human Amnion epithelial cells were obtained by enzymatic digestion of human 
amnion membranes from full term placentae. We used human placentae procured 
only from uncomplicated full-term cesarean procedures performed at Karolinska 
University Hospital, Huddinge. Placenta are procured after signed consent from 
the mother according to ethical protocol and permit number 2015/419-34/4. 
Tissue is collected after cesarean sections from pre-screened healthy mothers for 
 sterility and safety concerns. The protocol for hAEC isolation is based on mechano-
enzymatic procedure as previously described (82). Briefly, the amnion membrane 
was surgically removed from the surface of the placenta and washed multiple time 
with Ringers solution (Baxter, Sweden) to remove the blood from the membrane. 
A final wash in Saline solution (Fresenius kabi, Sevres, France) is performed to 
re-equilibrate pH to 7.4. The amnion membrane is equally distributed in 50 ml 
falcon tubes (approximately 2-3 gr of wet tissue per tube) and resuspended in 
TrypLE 10x solution (Life tech, Paisley, UK). All the tubes were transferred to 
a temperature-controlled rotator (IncubatorGeni, Bohemia, New York), and left 
at 37 °C in rotation at 35 rpm for 30 min to specifically remove epithelial cells. 
The remaining tissue is discharged and the dispersed epithelial cells collected and 
washed at least 2 times by centrifugation at 400 g for 5 min at 4 °C. The cell  pellet 
was resuspended in saline solution and filtered through 100 µm cell strainer to 
remove cell clumps and remaining small membrane fragments. 
13.1.4 In Vivo Cell Tracker 
Cryopreserved hAEC were thawed quickly in a water bath at 37 °C, centrifuged at 
450 x g for 5 min and resuspended in plasmalyte solution (Baxter, Norfolk, UK). 
Cells were counted with a Bürker chamber and viability was quantified by Trypan 
Blue exclusion (Sigma-Aldrich). Cells were directly labeled with the lipophilic 
DiR dye (1,1’-dioctadecyltetramethyl indotricarbocyanine Iodide; (product no: 
125964, Perkin Elmer, Waltham, USA), and cell viability was measured again 
(by Trypan Blue exclusion). DiR dye has a near infra-red emission wavelength 
with the excitation/emission range from 748/780nm. The staining solution was 
prepared at a final concentration of 5 µM dye in plasmalyte solution. The hAEC 
were suspended in the staining solution and incubated at 37 °C for 30 min with 
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mild rocking. Later, cells were sedimented at 450 g for 5 min and washed three 
times with cold plasmalyte to remove unbound dye. Each animal received one 
million hAEC resuspended in 200 µl plasmalyte, supplemented with 15 units(U)/
ml heparin (Orifarm AB, Stockholm, Sweden), and transplanted via tail-vein or 
directly into the parenchyma of the spleen. 
13.1.5 In Vivo Imaging System (IVIS) 
Anesthetized mice were placed into the IVIS chamber and images were captured 
using the IVIS spectrum camera (Perkin Elmer) at 1, 3 and 24 h. post cell trans-
plantation. Background level was quantified by transplanting unlabeled-hAEC in 
one mouse per group. At the end of total body scan, 24 h. post-infusion, mice were 
euthanized, and organs were removed and placed into the IVIS chamber for ex 
vivo imaging. Both total blood and plasma samples were collected and measured at 
24 h. post-transplant. Plasma samples were collected in a heparinized, Microvette® 
500 K2E tube (product no: 20.1339.100, Sarstedt, Germany) and centrifuged at 
450 g for 5 min. Blood and plasma samples were imaged with IVIS to quantify 
signal from cells in the circulation by seeding 200µl of total blood or plasma in 
a black 96 well plate and fluorescence was read with the IVIS spectrum camera.
13.1.6 Blood and Tissue Sampling 
Starting from the 5th week after human hepatocyte transplantation, the levels of 
circulating human albumin were monitored to estimate the level of repopulation 
of the mouse liver with human hepatocytes. Blood samples were collected from 
mice twice a month. The mice were placed in a restrainer and blood samples were 
collected from the tail vein using 27 gauge needle. 
When the experiments were complete the mice were anaesthetised using isoflu-
rane. Blood and internal organs (liver, lungs, spleen, kidneys) were harvested and 
portions were immediately flash frozen in liquid nitrogen and stored at -80 °C. 
The representative tissue was fixed in 4% formalin for 48 h. and embedded in 
paraffin. The tissue sections were sectioned to 4µm thickness and mounted on a 
Superfrost® Plus glass slides (VWR, Leuven, Belgium).
13.2 Immunostaining techniques
13.2.1 Fluorescence-Activated Cell Sorting (FACS) Analysis
The evaluation of surface markers expression was performed by flow cytometry. 
Flow cytometry was performed on both freshly isolated and cryopreserved hAEC. 
The hAEC were incubated for 30 min at 4°C in 100µl ice-cold PBS with specific 
antibodies (listed in Table below). 
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Table 1. List of antibodies used for flow cytometry.
 
Antibody Dye Clone Ig Host Diluition Company cat. Number 
CD326 (EpCAM) APC-conjugated HEA-125 IgG1 Mouse 1:10 Miltenyi  130-091-254 
CD105 (endoglin) PE-conjugated 266 IgG1 Mouse 1:20 BD 560839 
CD49f (alpha6-
Integrin) PE-conjugated GoH3 IgG2a Rat 1:5 BD 555736 
CD45 FITC-conjugated T29/33 IgG1 Mouse 1:10 Dako F0861 
CD44 (H-CAM) FITC-conjugated G44-26 IgG2b Mouse 1:5 BD 560977 
CD31 (PECAM-1) 
Alexa647-
conjugated 
WM59 
IgG1 Mouse 1:20 BD 561654 
Cells were either stained with single or multiple markers simultaneously, and sig-
nal discriminated by different detectors. Isotype controls were used to measure 
the level of non-specific background signal caused by primary antibodies. After 
primary antibody incubation, cells were washed to remove the unlabeled antibod-
ies and fixed with 2% BD™ stabilizing fixative (BD biosciences, San Jose, CA, 
USA) for 10 min at room temperature. The cells were centrifuged, resuspended in 
ice-cold PBS (300µl) and analyzed using BDCanto and FlowJo™_v10 software. 
13.2.2 Immunohistochemistry
Liver samples from mice were stained with human-specific antibodies; CPS1 (1:25) 
(Dako, Glostruo, Denmark), OTC (1:400) (Sigma, St. Louis, MO, USA) and/or 
CK8/18 (1:100) (ThermoFisher, Rockford, IL, USA) and tissues were counter-
stained with hematoxylin and eosin (HE) to quantify the level of engrafted cells. 
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13.3 Molecular techniques
13.3.1 DNA Analysis
To quantify human cells in different organs, murine tissues were crushed into 
a fine powder under liquid nitrogen, and 8 aliquots from each organ were col-
lected. Genomic DNA was isolated from tissue samples using the DNeasy Blood 
and Tissue kit (Qiagen, Hilden, Germany). Total human DNA content was esti-
mated using quantitative polymerase chain reaction (qPCR) with human-specific 
AluYb8 sequence (forward:5’CGAGGCGGGTGGATCATGAGGT3’, reverse: 
5’TCTGTCGCCCAGGCCGGACT3’, Invitrogen). Linearity and resolution limits 
were determined by diluting hAEC DNA in murine DNA at concentrations of: 
30%, 10%, 3%, 1%, 0.3%, 0.1%, 0.03% and 0.01%. Mouse liver DNA was used 
as a negative control. The sensitivity of the assay is such that one human cell in 
10.000 mouse cells could be detected. 
13.3.2 Elisa
From each mouse, 2 µL blood was collected, diluted in 198 µL diluent and assayed 
using the Quantitative Human Albumin ELISA Quantitation Kit (Bethyl Laboratory, 
TX, United States) according to the manufacturer’s protocol. Multiple measure-
ments were performed on each sample, at different dilutions (1: 100-100.000), 
in order to quantify the level of “humanization”. It is estimated that 1 mg/ml of 
circulating human albumin represents a 20% of repopulation with human hepato-
cytes (77, 83). A fresh standard curve (ranging from 15 to 200 ng/mL) made 
with human reference serum RS10-110-4 (Bethyl laboratory Inc., TX, USA) was 
included in each analysis.
13.3.3 Quantitative Real Time PCR
The RNA was isolated by lysing cells using Trizol™ solution (Thermo Fisher, 
Waltham, MA, USA) and the tissue samples were homogenized using iron beads 
using tissue homogenizer and RNA was isolated according to the manufacturer’s 
instructions. Total RNA was converted to complementary DNA using a high 
capacity cDNA kit (Thermo Fisher, IL, USA). The DNA was isolated from cells 
and tissue using DNeasy blood and tissue kit (Qiagen, Hilden, Germany). Gene 
expression was assessed using TaqMan™ assays (Thermo Fisher, Waltham, MA, 
USA). Few TaqMan™ assays were custom made to be specific to human and not 
to cross-react with mouse cells.
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Table 2. TaqMan assays.
No. Gene Assay No. Gene Assay 
1 PPIA Hs99999904_m1 34 NTCP Hs00914889_m1 
2 GAPDH Hs03929097_g1 35 HNF1a Hs00167041_m1 
3 CYP 3A4 Hs00430021_m1 36 HNF1b Hs00172123_m1 
4 CYP 3A7 Hs00426361_m1 37 HNF3a Hs04187555_m1 
5 CYP 1A1 Hs00153120_m1 38 HNF3b Hs00232764_m1 
6 CYP 1A2 Hs01070374_m1 39 HNF4a Hs00230853_m1 
7 CYP 2C9 Hs00426397_m1 40 HNF6 Hs00413554_m1 
8 CYP 2D6 Hs02576167_m1 41 HIF1A Hs00153153_m1 
9 CYP 2C8 Hs00258314_m1 42 DLK1 Hs00171584_m1 
10 CYP 2C19 Hs00426380_m1 43 NANOG Hs04260366_g1 
11 CYP2B6 Hs03044634_m1 44 SOX2 Hs01053049_s1 
12 UGT1A1 Hs02511055_s1 45 SOX17 Hs00751752_s1 
13 UGT1A6 Hs01592477_m1 46 OCT4 Hs00742896_s1 
14 UGT1A9 Hs02516855_sH 47 CK7 Hs01115174_mH 
15 UGT2B7 Hs00426592_m1 48 CK8 Hs02339474_g1 
16 UGT2B17 Hs00854486_sH 49 CK18 Hs01653110_s1 
17 A1AT Hs01097800_m1 50 CK19 Hs00761767_s1 
18 OTC Hs00166892_m1 51 ASGR1 Hs00155881_m1 
19 CPS1 Hs00157048_m1 52 MET Hs01565582_g1 
20 PAH Hs00609359_m1 53 CYP7A1 Hs00167982_m1 
21 ALB Hs00609411_m1 54 UGT2B10 Hs02556282_s1 
22 AFP Hs00173490_m1 55 LXRα Hs00172885_m1 
23 PXR Hs01114267_m1 56 LXRβ Hs01027215_g1 
24 CAR Hs00901570_g1 57 CYP7B1 Hs00191385_m1 
25 AHR Hs00169233_m1 58 SOX9 Hs01001343_g1 
26 FXR Hs01026590_m1 59 PPARα Hs00947536_m1 
27 P-gp Hs00184500_m1 60 PPARγ Hs01115513_m1 
28 MDR3 Hs00240956_m1 61 WNT1 Hs01011247_m1 
29 BSEP Hs00184824_m1 62 catenin, β Hs00355049_m1 
30 MRP2 Hs00166123_m1 63 Glutamine synthase Hs00365928_g1 
31 MRP3 Hs00978473_m1 64 Glucocorticoid receptor Hs00353740_m1 
32 MRP4 Hs00988717_m1    
33 BCRP Hs00184979_m1    
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14 AMMONIA CHALLENGE
The CPS1-D and CPS1 proficient liver humanized mice were characterized by 
their ability to metabolize ammonia. The ammonia challenge was performed on 
mice by an intraperitoneal injection of [15N] ammonium chloride (product number 
299251, >99% pure, Sigma-Aldrich, St. Louis, MO, USA) 4 mmol/kg of body 
weight. The level of ammonia was measured before and 30 min post-injection of 
ammonia using an Arkray pocket chem (Arkray, AT, Netherlands) according to 
the manufacturer’s instruction. 
15 STATISTICAL ANALYSIS
In all studies, data sets were compared by Mann-Whitney non-parametric tests, 
since the collected data were not normally distributed. Results are represented 
as histograms showing mean ± SD, or box and whisker plots showing median, 
25- and 75-percentiles. P-value < 0.05 was considered as significant (*P < 0.05; 
**P < 0.001; ***P < 0.0001). Data were analyzed with GraphPad Prism software, 
version 6 (GraphPad Software Inc., San Diego, CA, USA).
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16 RESULTS AND DISCUSSION
16.1 Paper 1
Isolation of Human Amnion Epithelial Cells According To Current Good 
Manufacturing Procedures.
The precise requirement for banking of any cell product for clinical use may vary, 
but it is highly recommended that all reagents used in the isolation procedure do 
not contain and come from animal origin. The practice of stem cell bio-banking has 
been growing in recent years due to supportive results in their use for cell therapies. 
Several countries have established cell banking practice to preserve stem cells and 
facilitate their research and clinical application (84). 
Although the published study was conducted under regular laboratory conditions, 
and are thus, not “According to Current Good Manufacturing Procedures” as the 
title suggests, the reagents and techniques were standardized so that they could be 
translated to protocols in a GMP-level facility. We make no claim of isolating these 
cells under GMP conditions, just the working out of the techniques with GMP grade 
reagents to facilitate a quick translation of the technology to a GMP level protocol. 
In this study, we have established a protocol to isolate amnion epithelial cells from 
the placenta with minimal contamination of other cell types. hAEC suspensions has 
been previously transplanted in mouse models of metabolic liver diseases, establish-
ing the safety and efficacy of hAEC (18, 28, 54). Based on our previous preclinical 
and clinical transplants using human hepatocytes, it is accepted that large numbers 
(billions) of donor cells may be required to correct metabolic diseases, and such large 
numbers of primary hAEC cannot be obtained from a single placenta. Combined, 
repeated hAEC infusions from multiple donors will most likely be required in clini-
cal practice. Thus, hAEC isolation and bio-banking is an essential step to have a 
sufficient number of hAEC ‘off-the-shelf’ that can be transplanted “on-demand”. 
Amnion-derived cells are classified as Advanced Therapy Medicinal Product (ATMP) 
according to the European Union (EU) classification. Criteria for ATMPs can be 
found in Article 17 of Regulation (EC) No. 1394/2007. The aim of project 1 was the 
isolation of hAEC from the full-term placentae in near GMP conditions. Our proto-
col is based on minimal manipulation (enzymatic isolation and cryopreservation). 
A description of the isolation procedure is described in the methodology section 
(13.1.3). The workflow of the hAEC isolation procedure is represented in Figure 10. 
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Figure 10. Amnion epithelial cell isolation from full-term human placenta. An X-shape 
incision is made on the placenta (A) and amnion membrane is manually peeled off (B and 
C). The amnion membrane is washed with Ringers (D) and digested using TrypLE  solution 
at 37°C in continuous agitation (E). Resulting cells are resuspended in cryosolution, 
 transferred in freezing box and later moved in liquid nitrogen vapors (F). R. Gramignoli 
et al., Curr. Protoc. Stem Cell Biol 2016. 37:1E.10.1-1E.10.13.
The efficiency and selective isolation of hAEC have been confirmed by histological 
analysis, where the removal of epithelial cells was confirmed after enzymatic digestion.
Figure 11. Amnion membrane before and after the hAEC isolation procedure. R. Gramignoli 
et al., Curr. Protoc. Stem Cell Biol 2016. 37:1E.10.1-1E.10.13. 
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All the placenta tissues analyzed in the study have been collected at the Karolinska 
University Hospital (GYN/OB Department) with properly signed consent form 
and they are transported to the lab within an hour of delivery. 
The release of the final hAEC product is based on tripartite components commonly 
required by International Agencies: sterility, viability, and identity. The presence 
of cell surface markers has been recognized as a method to validate hematopoietic 
and mesenchymal cells, thus we use this technology to identity amnion-derived 
cells. To validate hAEC products, we quantified expression of epithelial markers, 
such as CD326 and CD49f, by flow cytometry. Such analysis confirmed that the 
preparations showed minimal contamination of the epithelial cells with mesenchy-
mal stromal cells (CD105 and CD44 positive cells) endothelial (CD31 positive) 
or hematopoietic cells (CD45 positive).
16.2 Paper 2
Effect of cryopreservation on Human Amnion Epithelial Cells
The long-term preservation (banking) of clinical-grade cell products, without 
compromising safety and efficacy, is essential to meet the required number of cells 
for transplantation. From the clinicians’ point of view, the sine qua non conditions 
in cell therapy are, primarily, ‘safety’, then ‘therapeutic efficiency’ and finally 
‘availability/sufficient quantity’. 
In our study, we have standardized a method for hAEC isolation and banking with 
GMP grade reagents. We validate hAEC batches by flow cytometry, based on the 
same surface markers we validated in paper 1, confirming marker expression before 
and after cryopreservation to evaluate the effects of cryopreservation on cells. 
Fresh Cells
hAEC Isolation
Cryopreserved hAEC
Staining
Flow analysis
Figure 12. Project workflow. The hAEC were isolated from the placenta and characterized 
by flow analysis with fresh and cryopreserved cells. Created with Biorender.com
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Amnion epithelial cells were isolated as described in paper 1. In this study, hAEC 
were harvested from 14 different donors, cryopreserved and analyzed for purity 
using flow cytometry. Cryopreservation was performed using UW solution, supple-
mented with 10% DMSO. The density of 10 million cells per mL of cryopreser-
vation media was chosen to freeze the hAEC. To confirm homogenicity, hAEC 
suspensions were stained for epithelial markers (CD326 (EpCAM) and CD49f 
(Integrin α-6 molecule), mesenchymal; CD105 (Endoglin molecule) and CD44, 
hematopoietic; CD45 and endothelial marker CD31. Cell viability was determined 
by Trypan blue exclusion at the time of isolation and after thawing. 
Surface marker expression analyzed before the cryogenic procedure was not sig-
nificantly altered after thawing, providing evidence that the same cells that were 
isolated, were recovered after freezing and thawing. We documented a decrease 
in cell viability of approximately 12% and up to a 35% decrease in cell recovery. 
We also monitored the presence of immunomodulatory molecules, such as non-
canonical HLA-Ib and ecto-enzymes at the transcriptome level and by flow analysis. 
The expression of potent immunomodulatory molecules such as (HLA-G/-E/-F) 
are likely factors that explain the long term survival of hAEC and the ability to 
avoid immune recognition and rejection, in allogenic and even xenogeneic trans-
plantation. We confirmed the low expression of polymorphic HLA-Ia as well as 
the lack of expression of HLA class II molecules. 
We analyzed the ectoenzymes expressed by hAEC; CD39, CD38, and CD73, 
ectoenzymes that play vital roles in modulation of the host immune system (85). 
Along with the other immune-suppressive molecules, adenosine (ADO) has been 
identified as an important immunomodulator. Normally, ADO is produced via a 
canonical pathway; CD39, CD73 and an alternative pathway; CD38, CD203a/
PC-1, CD73. An ecto-nucleoside triphosphate diphosphohydrolase (CD39) con-
verts ATP to ADP and then into AMP and finally CD73 converts AMP into ADO. 
Alternatively, CD203a/PC-1 can convert ADP ribose or ATP to AMP and finally 
metabolize to ADO by CD73. The expression of these potent immunomodulatory 
ectoenzymes was present on all hAEC cases. 
It is known that hAEC possess some degree of plasticity, likely due to the unique 
derivation of these cells prior to gastrulation and the specification of the three 
germ layers. The expression of characteristic stem cell genes, NANOG, SOX2, 
and OCT4 were identified in all hAEC cases. NANOG and SOX2 were expressed 
at 100 and 1000-fold different levels when compared to iPS cells, whereas OCT4 
expression was the same as iPS cells. 
Cell migration, invasion, tissue remodeling, and proliferation are important steps 
that occur after cell transplantation. Important MMPs involved in cell mobilization 
are MMP 2 and 9 (86), and MMP 2 and 9 were expressed in all our hAEC cases. 
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Active MMPs are regulated, in part, by the tissue inhibitors of metalloproteinases 
(TIMPs). Maintaining the balance between MMPs and their inhibitors is critical for 
tissue remodeling. Finally, hAEC do not express telomerase reverse transcriptase 
(TERT), showing they are not immortal.
In conclusion, hAEC can be efficiently cryopreserved for clinical use without 
evidence of significant alteration of the surface receptors that are used to identify 
the cell population. 
16.3 Paper 3
hAEC transplantation as a treatment for Phenylketonuria 
Hepatocytes have always been the first choice of cells for transplantation to treat 
(congenital and acute) liver disease. An alternative source of cell needs to be iden-
tified as the availability of hepatocytes are not sufficient to meet all the demands 
for cell therapies. In paper 3, (currently reviewed and in revision based on the 
reviewer’s comments for resubmission) we tested the hypothesis that hAEC can 
correct another inborn error of metabolism: PKU. Similarly to what we did in a 
previous study, where animals were rescued from another amino acid disorder 
(MSUD), we transplanted human amnion cells into an immunocompetent mouse 
with mutations in the gene that causes PKU (Pah). Our previous study with MSUD 
provided evidence of in vivo hepatic differentiation of hAEC based on correc-
tion of the genetic defect and expression of many other genes characteristic of 
mature hepatocytes, suggesting hAEC can engraft and differentiate to cells that 
express mature hepatic genes at levels that are sufficient to support genetic based 
metabolic liver diseases. All the more importantly, a xenotransplant of hAEC was 
performed on the MSUD mice, animals with a normal immune system, and the 
cells were accepted and were sustained, long-term in the mice without providing 
drug-immunosuppression.
PKU is a rare disease that affects male and females in equal numbers. PKU babies 
are normal when they are born and in the neonatal period. Later, symptoms start 
to appear such as, vomiting, lethargy, seizures and pale pigmentation develops in 
skin and hair due to the high levels of phenylalanine. Accumulation of phenylala-
nine also prevents the transport of amino acid across the blood-brain barrier. This 
results in disruption of amino acid synthesis in brain due to inhibition of synthesis 
of neurotransmitters, which leads to severe mental disabilities. 
In this study, we used a Pah mutant mouse strain which shows symptoms commonly 
observed in human patients, including high level of phenylalanine in the blood. 
Based on our clinical evidence collected after 27 years of hepatocyte transplants, 
it is established that to correct most of the liver based genetic defects (excluding 
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hemophilias), we need to repopulate the donor liver with more that 10% donor 
cells to compensate for the missing hepatic gene function. Here, each mouse was 
injected with a total number of 15 million cells directly into the liver by  multiple 
injections over the first 28 days. Cell transplantation was performed without 
providing immunosuppressive drugs to animals with a normal immune system.
Figure 13. Project workflow. The hAEC were transplanted directly into the PKU mouse 
liver multiple times. The mice were euthanized on day 100 and analysed for gene profiling. 
Created with Biorender.com
The DNA and RNA analysis 100 days post-transplantation revealed hAEC engraft-
ment and expression of human PAH enzyme in the mouse liver. On average, livers 
were measured to contain 3.7% human DNA and a similar level of human PAH 
expression (4.6% of normal). There is a partial correction in serum PHE with reduc-
tion up to 60% when compared to the wild type mouse. Brain PHE was corrected 
to the level that it is not significantly different when compared to wild type mice. 
This implies hAEC transplants can provide substantial improvement of PHE levels 
in the brain and suggest that this therapy would provide disease correction. This 
data again shows the plasticity of hAEC and potential to become hepatocyte-like 
cells when transplanted to the liver. In addition, transcriptome analysis revealed that 
hepatic liver genes, commonly expressed in mature hepatocytes, were expressed 
at similar levels in hAEC post-transplant. Pre-transplant, hAEC do not express 
hepatic genes (including PAH) except for very low levels of CPS1 and UGT1A9, 
supporting the hypothesis of in vivo hAEC maturation into hepatocyte-like cells 
when they are transplanted into the liver. Apart from PAH expression, we measured 
mature liver like expression of other enzyme genes such as OTC, A1AT, CPS1, 
and BSEP, supporting the hypothesis that hAEC transplants could be effective in 
patients with these deficiencies.
Finally, we never observed neoplastic transformation of the cells post-transplant, 
consistent with previous studies (18, 26). 
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In summary, the efficacy of hAEC transplants was demonstrated in a mouse 
model of where injection of hAEC significantly improved the PHE levels. The 
xeno-transplant was performed in an immunocompetent mouse, supporting our 
hypothesis that hAEC can be transplanted without immunosuppressive drugs. 
16.4 Paper 4
A liver-humanized mouse model for carbamoyl phosphate synthetase 
 1-deficiency (CPS1-D)
Animal models are usually used as a surrogate of human biology. Small animals 
are used and due to their small size, they can be handled easily and can be geneti-
cally manipulated. A major barrier in translating the preclinical data to the clinic 
is the biological difference between man and mouse. A notable example was 
Fialuridine (FIAU), which was used to treat HBV infection. Preclinical studies in 
mice showed no toxicity, however, when it was used on human patients, it resulted 
in severe liver injury (87). 
Figure 14. Project workflow. The FRGN mice were transplanted with CPS1-D or healthy 
hepatocytes. The blood sampling was performed to estimate the level of humanization 
using ELISA and ammonia challenge was performed to analyse the ammonia metabolism 
using MS. Finally, mice were euthanized and analysed for histology and enzyme assay. 
Created with Biorender.com
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To overcome such issues, chimeric mouse models, where the native mouse hepato-
cytes are replaced by human cells have been developed by our group and others 
(77). Such ‘liver-humanized mice’ may provide a faithful model to investigate 
metabolic liver diseases in actual disease-affected human hepatocytes. In paper 4, 
we described the successful generation of a novel mouse model for one of the urea 
cycle diseases; carbamoyl phosphate synthetase 1-deficiency, CPS1-D which is 
an autosomal recessive disorder with an occurrence estimated to be around 1 in 
1,300,000 live births in the USA (88). 
In this study, we used our FRGN mouse model, a mouse with a knockout of the 
Fah, Rag2, and IL2rg genes which was cross bread with Non-Obese Diabetic 
(NOD) mice (77). These FRGN mice readily accept human cells and can be 
highly repopulated with normal human hepatocytes or CPS1 deficient cells. Mice 
repopulated with normal hepatocytes has been previously described and served as 
controls for the present study.
Since the mouse is a model of a defect in Fah, the human disease corresponding 
to tyrosinemia type 1, as with the human patients the FRGN mouse needs to be 
maintained on the drug (2-(2-nitro-4-trifluoro-methylbenzoyl)1,3-cyclohexedione, 
NTBC), to limit lethal liver damage. A NTBC on/off cycle is used to generate 
loss of mouse hepatocytes which can be compensated by the transplantation and 
proliferation of FAH-proficient donor human hepatocytes. 
Mice were transplanted with 1 million normal human hepatocytes (CPS1 proficient) 
or CPS1-D hepatocytes isolated from a patient who had undergone liver trans-
plantation to correct the disease. Post transplantation of human cells, the level of 
humanization, or repopulation of the mouse liver with human cells was estimated 
by measuring the concenntration of human albumin in the blood of transplanted 
mice using ELISA. End stage analysis was performed on mice that have achieved a 
minimum of 4 mg/mL human albumin, which is estimated to correlate with ~80% 
repopulation with human hepatocytes (77). An ammonia challenge was performed 
on repopulated mice by infusing [15N]H4Cl (4mmol/kg of body weight) through 
tail vein and blood ammonia levels were analyzed before infusion of ammonium 
chloride and 30 min post infusion. Basal ammonia levels in CPS1-D mice were 
higher than in control mice. Moreover, after the ammonium chloride challenge, 
CPS1-D mice displayed a significant delayed clearance of ammonia when com-
pared to control animals. These observations from the mice are consistent with 
what is observed with human patients with the same disease.
Amino acids were also analyzed on mice repopulated with normal and CPS1 
deficient cells. As also observed in human patients with this disease, the level 
of glutamine and glutamate were elevated in CPS1-D mice compared to control 
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mice that received CPS1-proficient human hepatocytes. Other amino acids such 
as citrulline, arginine, and alanine did not show a significant difference between 
the two groups. 
The enzyme activity was measured to verify the CPS1 defect in the mice. The 
CPS1-D mouse showed only 20% of the enzyme activity when compared to mouse 
transplanted with healthy human hepatocytes. To determine if other urea cycle 
enzymes were affected in the CPS1-D mice, OTC (ornithine carbamoylase) gene 
expression was analyzed and found to be expressed at normal levels. Histological 
analysis shows CPS1 and OTC staining on highly humanized mice. The majority 
of the liver sections stained for human-specific CPS1 and OTC and remaining 
unstained mouse hepatocyte are shown in Figure 15.
In summary, CPS1-D human hepatocytes can be used to generate highly repopu-
lated liver- humanized mice. The CPS1-D mouse exhibits characteristic symp-
toms of human CPS1-D. Liver-humanized mouse will be more informative than 
traditional mouse models and could play an important role in cellular and gene 
therapies (including the latest gene-editing technologies such as CRISPR). Since 
the target cell in liver-humanized mice is actual disease affected human hepato-
cytes, preclinical studies conducted on liver-humanized mice will be critical to 
investigate the safety and efficacy of gene editing therapies. 
Figure 15. Histology. The liver sample collected from highly humanized mouse stained for 
CPS1 or OTC. The mouse hepatocytes and human hepatocytes can be clearly distinguished, 
showing human hepatocyte repopulation in mouse liver.
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16.5 Paper 5
Evaluation of different routes of administration and bio-distribution of 
human amnion epithelial cells in mice
The route of administration plays an important role in delivering a cell to the  target 
organ, in our case, the liver. In this preclinical study, we intended to validate an 
efficient route of hAEC administration to the liver with minimal engraftment in 
other organs. The FRGN mouse model was used as a recipient for hAEC infusion 
and the bio-distribution was monitored. We characterized donor cells from three 
different hAEC cases by flow cytometry as previously described (with anti- CD326, 
CD49f, CD105, CD44, CD45, CD31). 
Figure 16. The project workflow. The FRGN mice were transplanted with hAEC (DiR 
labelled) via intra-splenic or tail vein. The distribution of hAEC were monitered on live 
mice using IVIS at 1, 3, and 24 h. The mice were euthanized at 24 h and organs were 
 analysed for DNA and histology. Created with Biorender.com.
To optimize cell delivery to the liver, we compared transplantation of hAEC via the 
spleen or systemically through the tail vein in mice. To trace the bio-distribution 
after transplantation, hAEC was labeled with a near infrared DiR dye and viewed 
with an in vivo imaging system (IVIS) at 1, 3, and 24 h. post-transplant. The locali-
zation of cells was observed in real-time, and in live animals. Twenty-four hours 
post-injection, the organs were collected and DNA was isolated. The presence of 
human hAEC DNA was quantified by PCR using a human-specific AluYb8 primer. 
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The results clearly indicated the majority of the transplanted hAEC were detected 
in the liver when the transplants were conducted via the spleen, with little or 
no human DNA detected in other organs (heart, lungs, kidneys, and intestine) 
(Figure 17). On average 4.7 x 105 and 6.5 x 104, cells were tracked in the liver 
when transplanted via intrasplenic and tail-vein, respectively. 
Histological studies confirmed hAEC integration into the mouse liver parenchyma, 
when injected through the spleen. 
To conclude, our data support an efficient and safe delivery of hAEC into the liver 
achieved by intra-splenic infusion, a method frequently used in mice to model portal 
vein transplants in human patients. On the contrary, tail-vein infusion results in a 
different distribution pattern with cells mainly located in the lungs with significant 
localization in multiple other organs. 
 
1h 3h 24h
r 
Figure 17. IVIS imaging. Transplanted hAEC via the spleen have localized to the liver 
as shown here at 1, 3, and 24 h. post-transplantation. RC.Srinivasan et al., Cytotherapy 
2019. 21: 113-124
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17 REFLECTION ABOUT ETHICAL 
 CONSIDERATIONS WITHIN THE PROJECT
My project deals with hAEC as an alternative source for hepatocytes for treating 
liver metabolic diseases. The hAEC are isolated from full-term placenta after live 
birth. The placenta is normally discarded after the delivery, which makes them a 
minimal ethical concern. The human placentae utilized in my studies have been 
collected from healthy mothers after a caesarian section procedure and proper 
donation consent was signed. In paper 1, the ethical permit no 2015-419-31/4 
was obtained. 
The FRGN mouse model was used for the paper 4 and 5. The FRGN mouse has 
a mutation in Fah gene, which will cause liver injury. Lethal liver failure can be 
prevented by supplementing animals with NTBC drug. The mice receive humane 
care and provided with water and food accessible throughout the experiment. Mice 
approximately 6 weeks of age were transplanted with cells. 
The aim of paper 3, is to analyze the bio-distribution of the hAEC after transplant-
ing them through the spleen or intravenously. We have separate ethical permission 
to transplant hAEC through tail vein (B102-15) and spleen (70-15). The mice were 
humanely euthanized at the end of the experiment and organs were collected for 
further analysis. Animal experiments were required to investigate and optimize 
the route of administration of hAEC, to efficiently target the liver and to have 
a better understanding of the migration and engraftment of the cells. As a pre-
clinical study, this data can be useful to the regulatory authorities to determine 
the safety of the procedure needed to take the hAEC to the clinic to treat patients 
with metabolic liver disease.
Finally, the PKU project (paper 3) required xenotransplants and was performed 
at the University of Pittsburgh. The ethical permit was approved by the same 
University (0905698B-12). The PKU mouse model was transplanted with hAEC 
directly into the liver multiple times during the first 28 days. Since human patients 
with inborn errors of metabolism may require to be treated at a very early stage, 
Pahenu2 mouse was treated at an early stage (before weaning) to model the timing 
of a clinical transplant. Project results support the safety and efficacy of hAEC 
repeated transplants, supporting perinatal stem cell translation into the clinic. 
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18 FUTURE PERSPECTIVE 
The research on hAEC over the last decade has led to a better understanding of 
their immunomodulation, immunosuppressive and in vivo differentiation ability. 
Our results have shown the potential of hAEC for liver cell therapy. 
In paper 1, we have shown the isolation of hAEC with GMP grade reagents and 
we would like to move the isolation procedure to a GMP facility for banking of 
cells for future cell therapy. Our preclinical studies show that the cells we will 
isolate can be preserved and bio-banked for future cell therapy. Currently, we have 
an ethical permit to transplant hAEC into 10 patients to treat liver diseases that 
might otherwise be treated by hepatocyte transplantation. 
Paper 2, the cryopreservation procedure for hAEC can be improved to increase 
the viability after thawing procedure. There are different cryopreservation media 
now available which can be used to reduce the cell loss during cryopreservation 
procedure. In the future, we would also like to culture the hAEC in vitro to prolifer-
ate and provide more cells for transplantation, but so far we have not succeeded. 
New technologies such as organoid culture might be helpful for cell proliferation 
without altering the characteristics of the hAEC. 
In Project 3, we created liver-humanized mouse models of the human disease 
CPS1-deficiency. In future studies this highly human relevant model can be used 
to investigate the safety and efficacy of cellular tharapies such as hAE transplants, 
or gene or CRISPR-based therapies. We are also working on another liver human-
ized mouse model for Ornithine transcarbamylase, another urea cycle disorder. 
Treating and rescuing the mouse from metabolic liver diseases will be important 
preclinical studies and help us in translating hAEC to the clinic. As these mouse 
models are humanized with human hepatocytes the symptoms observed in the 
mice are consistent with what we see in patients.
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that you can do for me. Madhurya, I’m lucky to have such a lovely wife. I did 
not know you two years ago, but now I cannot imagine anything without you. I 
have admired your patience and calmness (except the days you fight with me). My 
brother Vasantharaman, thanks for your support and I owe a lot to you.
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